Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Surprises Analysts With CE Mark For Freestyle Libre 3

Executive Summary

The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.

You may also be interested in...



Minute Insight: Abbott’s Libre 3 Breaks In To UK Market

The NHS will now pay for the Libre 3 system as part of its NHS Supply Chain Network.

Market Intel: Glucose Monitor Market Set To Explode As Patients Access Better Devices

The market for blood glucose monitoring devices is expected to see double-digit growth, reaching $19.7bn by 2025. This growth is driven largely by the rising demand for smaller, more convenient continuous glucose monitoring (CGMs) devices with improved digital capabilities.

Dexcom Outlines Three-Pronged Growth Strategy To Reach $4-4.5BN Revenue Goal By 2025

Dexcom’s growth strategy includes growing its core business, expanding into pharmacy sales channel, and expanding into new markets.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT142804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel